Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration

Open-Label, Multiple Ascending Dose Phase 1b/2a Study of the Safety and Tolerability of Intravitreal (IVT) EYC-0305 in Patients With Neovascular Age-Related Macular Degeneration

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07587515

Acronym

OVERTURE

Enrollment

Registered

2026-05-14

Start date

2026-05-19

Completion date

2028-05-01

Last updated

2026-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neovascular (Wet) Age-Related Macular Degeneration

Keywords

EYC-0305, TransCon aVEGF, wet AMD, neovascular AMD, treatment naive, Eyconis, anti-VEGF

Brief summary

This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.

Interventions

BIOLOGICALEYC-0305

Extended-delivery anti-VEGF

Study design

Allocation

NON_RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Men or women 50 years and older with neovascular (wet) AMD meeting all study-specified eligibility criteria * Willing and able to comply with clinic visits and study-related procedures * Provide signed informed consent

Exclusion criteria

* Known hypersensitivity or known allergy that would preclude study drug administration * Inability to obtain ophthalmic imaging, eg, due to media opacity, inadequate pupillary dilation, allergy to fluorescein dye or lack of venous access * Uncontrolled diabetes mellitus * History of cerebrovascular accident (CVA) or myocardial infarction within 180 days of the Day 1 visit * Renal failure, dialysis, or history of renal transplant * Concurrent psychiatric or medical condition that in the opinion of the Investigator will interfere with study participation or completion * Pregnant or breastfeeding women

Design outcomes

Primary

Measure	Time frame
Incidence and severity of ocular treatment-emergent adverse events (TEAEs)	Week 72
Incidence and severity of systemic treatment-emergent adverse events (TEAEs)	Week 72

Countries

United States

Contacts

CONTACTKim Reed, OD, FAAO

info@eyconis.com1-866-392-6647

CONTACTKaren Chu, MS